

## eIF2-alpha, Human Recombinant

<b>Catalog No.</b>	CRE302-2 CRE302-10	<b>Quantity:</b>	2 µg 10 µg
<b>Description:</b>	Recombinant Human Eukaryotic Initiation Factor 2-alpha has a MW = ~36 kDa.		
<b>Source:</b>	Sf9 cells		
<b>Formulation:</b>	Sterile filtered and lyophilized, carrier protein free.		
<b>Purity:</b>	>95% as determined by SDS-PAGE. Purified via sequential chromatography.		
<b>Endotoxin Level:</b>	<0.1 ng/µg of protein		
<b>Biological Activity:</b>	Recombinant human eIF2-α is phosphorylatable <i>in vitro</i> , using either immunoprecipitated active PKR or extracts from IFN-γ stimulated HEK 293 cells. This phosphorylation can be monitored by Western blot analysis using a phosphorylation site specific antibody directed to eIF2-α [pS51] in conjunction with chemiluminescence detection methods. Optimization of the cell stimulation protocol, cell lysis procedure, and reaction conditions may be required for each specific application.		
<b>Reconstitution:</b>	<b>Centrifuge vial prior to opening.</b> Reconstitute lyophilized recombinant human eIF2-α in PBS, to a concentration of 0.2-1.0 mg/ml. Following reconstitution, the protein solution should be supplemented with 1 mM β-mercaptoethanol (final concentration) and 10% glycerol (final concentration) to prevent precipitation. The optimal concentration should be determined by the user for each specific application.		
<b>Storage &amp; Stability:</b>	Store lyophilized recombinant human eIF2-alpha at 2-4°C, preferably desiccated. After reconstitution and supplementation with β-mercaptoethanol and glycerol, aliquot. eIF2-alpha solutions are stable at 2-4°C for up to 2 weeks. For maximal stability, store aliquots at ≤ -20°C. <b>Avoid repeated freeze-thaw cycles.</b> When stored as instructed, product is stable for one year from date of receipt.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

